NeuroScientific to acquire stem cell technology for Crohn’s disease treatment
PERTH: NeuroScientific Biopharmaceuticals Ltd. (ASX:NSB) announced plans to acquire StemSmart™, a patented stem cell technology from Isopogen WA Ltd., aimed at developing treatments for immune-mediated inflammatory disorders, including refractory Crohn’s disease. The acquisition, subject to shareholder and regulatory approvals, includes…